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SI/CTR Abstract 
 
DOWN REGULATION WITH LUTEAL GnRH AGONIST THERAPY IN EUPLOID EMBRYO 
TRANSFERS DOES NOT IMPACT PREGNANCY RATES 
 
Isabelle Levin BA, Keri Bergin MD, Dmitry Gounko BS, Joseph Lee BA*, Alan Copperman MD 
 
 
Introduction​: Gonadotropin-releasing hormone (GnRH) agonists have been used during 
assisted reproductive technology (ART) treatment for pituitary suppression and stimulation. 
Currently, clinical opinion is divided about whether GnRH agonist therapy improves pregnancy 
rates when used for luteal down-regulation in a frozen euploid embryo transfer (FET). This study 
evaluated the clinical utility of GnRH agonist down-regulation in single, euploid FET cycles.  
 
Methods​: A retrospective analysis was performed, using data from patients who underwent a 
single, euploid FET cycle from 2012 to 2019. Patients were segregated into two cohorts: Group 
A: single, euploid FET with down-regulation using GnRH agonist; Group B: single, euploid FET 
without down-regulation using GnRH agonist. Primary outcomes include pregnancy rates 
among cohorts.  
 
Results​: Group A demonstrated a pregnancy rate of 72.92% in 96 cycles. Group B 
demonstrated a pregnancy rate of 73.27% in 5,668 cycles. There was no difference in 
pregnancy rates between groups, X2(2, N = 5764) = .0061, p = .94. A subgroup of patients 
(n=5) with endometriosis in Group A achieved an 80% (4/5) pregnancy rate.  
 
Discussion​: Single, euploid FET cycle pregnancy rates were not affected by the use of 
down-regulation with a GnRH agonist. Increased pregnancy rates found with prolonged GnRH 
agonist use in other studies weren’t seen with short term use for FET cycles. Future research 
should focus on molecular markers and gene transcription signatures to attempt to define 
whether there is an ideal population of patients who would benefit from GnRH agonist 
down-regulation prior to FET. 
